BioWorld Science

Sep. 6, 2012

View Archived Issues

Novel antithrombotic agents presented by Bristol-Myers Squibb

Read More

New tamsulosin prodrugs prepared by Synthon

Read More

Affectis Pharmaceuticals presents novel P2X7 receptor antagonists

Read More

Novel monoclonal antibodies patented by IRM and Novartis

Read More

Mepolizumab reduces exacerbation rates in asthma patients

Read More

Third patient successfully treated with Pluristem's PLX cells

Read More

Phase I/II ublituximab trial begins in B-cell non-Hodgkin's lymphoma

Read More

Researchers at Zyngenia disclose novel fusion proteins

Read More

Light study of Contrave experiences accelerated enrollment

Read More

Oncothyreon expands phase II trial of PX-866

Read More

Novel S1P4 receptor antagonists synthesized by Biogen Idec

Read More

ImmunoCellular Therapeutics completes enrollment in ICT-107 trial

Read More

BT-2111 shows promise in animal models of breast cancer

Read More

Adynxx's AYX-1 set to move to phase II

Read More

Targacept to develop TC-5214 in overactive bladder

Read More

Phase II results demonstrate efficacy of QMF-149 in patients with persistent asthma

Read More

ALV-003 receives FDA fast track designation for celiac disease

Read More

New lysophospholipid S1P1 receptor agonists presented at ACS meeting

Read More

Rienso receives Swiss marketing authorization

Read More

NPS Pharmaceuticals updates plans for Natpara BLA

Read More

Baxter begins phase I monoclonal antibody trial in patients with solid tumors

Read More

Acadia Pharmaceuticals completes enrollment in phase III pimavanserin trial

Read More

Study evaluates dose-response of umeclidinium in COPD

Read More

Meda to buy Jazz Pharmaceuticals' women's health business

Read More

FDA extends PDUFA date for Ravicti NDA

Read More